论文部分内容阅读
自六十年代改造青霉素结构以来,具各种特点的新β-内酰胺抗生素对克服临床出现的细菌耐药性问题起了极其重要的作用。近几年来,由于筛选新抗生素的模型有了重大改进,发现了过去不易筛选得到的一群结构不同于青霉素和头孢菌素的新型β-内酰胺抗生素;如具β-内酰胺单环结构的新抗生素诺卡霉素(Nocardicin A)和磺霉素(Sulfazecin),具氧杂青霉烷结构的棒酸(Clavulanic acid)等,它们都各具其特点,尤其从罕见新菌株的次级代谢产物中,发现了具碳杂青霉烯结构的硫霉素
Since the transformation of penicillin structures in the 1960s, a variety of new β-lactam antibiotics have played an extremely important role in overcoming the clinical emergence of bacterial resistance. In recent years, due to the significant improvement of the model for screening new antibiotics, a new group of β-lactam antibiotics different in structure from penicillins and cephalosporins that were not easily screened in the past have been found. For example, new β-lactam monocyclic structures The antibiotics Nocardicin A and Sulfazecin, the Clavulanic acid with the oxapenem structure, etc., each of which has its own characteristics, in particular from the secondary metabolites of rare new strains In the discovery of a carbapenem structure of thiophanate